Drug Trial Radar · NCT04179669
Safety and Efficacy of IBI306 in HeFH Patients
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Dec 20, 2019
Primary completion
Jun 30, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol (LDL-C) uptake. In the phase I study, IBI306 was shown to be safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and lipoprotein (a) in healthy subjects. This study is a randomized, double-blind, placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the efficacy and safety of a novel PCSK-9 anti-body, IBI306, in Chinese patients with heterozygous familial hypercholesterolemia.
Conditions
- Heterozygous Familial Hypercholesterolemia
Interventions
IBI306Drug
Administered by subcutaneous injection
placeboDrug
Administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of LDL-C decreased from baseline injection.Time frame: at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.